Alseres Pharmaceuticals, Inc. (ALSE)
Stock analysis · OTC · Healthcare · Biotechnology
Alseres Pharmaceuticals, Inc. (ALSE) is a publicly traded company in the Healthcare sector. Latest price: $0.01. Market cap $398.25K. Trailing PE -0.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →Proprietary Signals
About Alseres Pharmaceuticals, Inc.
Alseres Pharmaceuticals, Inc. focuses on creating both diagnostic and therapeutic solutions, with a primary emphasis on ailments affecting the central nervous system. Their flagship experimental compound is Altropane, a molecular imaging agent developed for identifying and diagnosing Parkinson's disease and dementia. Founded in 1972, the company was previously known as Boston Life Sciences, Inc. before officially changing its name to Alseres Pharmaceuticals, Inc. in June 2007. Its operations are headquartered in Auburndale, Massachusetts.
Valuation
| P/E (TTM) | -0.00× |
|---|---|
| P/S (TTM) | 0.84× |
| P/B | -0.00× |
| P/FCF (TTM) | -0.24× |
| EV / EBITDA | -16.68× |
| EV / Sales | 17.11× |
| Earnings Yield | -1537457.16% |
| Free Cash Flow Yield | -423.58% |
Fundamentals
| Enterprise Value | $8.10M |
|---|---|
| Revenue (TTM) | $473.73K |
| Net Income (TTM) | -$6.12B |
| Free Cash Flow (TTM) | -$1.23M |
| Net Debt | $7.71M |
| Working Capital | -$1.32M |
| Gross Margin | 95.00% |
| Operating Margin | -204.76% |
| Net Margin | -198.85% |
| Return on Equity | 5.04% |
| Return on Invested Capital | 76.81% |
Peers
Recent News
- No recent news available.
Related
Browse more tickers: sitemap